More importantly, we provide preclinical and clinical evidence that PTHrP also causes cachexia that frequently complicates ccRCC and that both hypercalcemia and cachexia in ccRCC can be managed with pharmacological HIF2 inhibitors. This evidence concerns the gene PTHLH and hypercalcemia disease.